Before founding CereMark Pharma, Dr. Chilton was VP of Business Development for Cardinal Health Nuclear Pharmacy Services. He held a similar role while with PETNet Solutions. During his tenure at both organizations, Dr. Chilton led and developed successful collaborations with academia and pharma in creating enduring partnerships, commercial and research ventures, and successful strategies around developing and launching several diagnostic imaging and therapeutic radiopharmaceuticals. 

Prior to that, Dr. Chilton was an Associate Professor at Wake Forest University’s School of Medicine, Division of Radiological Sciences, where he was recognized as one of the “Twenty-five Pioneers of Nuclear Pharmacy” by the American Pharmaceutical Association (APhA). He was a member of the Committee on Revision and Expert Committees of the United States Pharmacopeia (USP). He was elected and appointed to several positions in the Society of Nuclear Medicine and Molecular Imaging (including receiving the SNMMI Presidential Distinguished Service award) and served as a member of the editorial board of the Journal of Nuclear Medicine for 10 years. Dr. Chilton is also a past president of the American Board of Science in Nuclear Medicine (ABSNM), a Diplomate of the ABSNM and was recognized as a Fellow of the American Society of Healthcare Pharmacists (ASHP). 

Dr. Chilton received his BS degree in Pharmacy from Mercer University’s School of Pharmacy, a Doctor of Pharmacy from the University of Tennessee Health Sciences Center and a Master of Business Administration from the Babcock School of Management, Wake Forest University.